Unveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy - Bodansky, Aaron; Yu, David JL; Rallistan, Alysa; Kalaycioglu, Muge; Boonyaratanakornkit, Jim; Green, Damian J.; Gauthier, Jordan; Turtle, Cameron J.; Zorn, Kelsey; O’Donovan, Brian; Mandel-Brehm, Caleigh; Asaki, James; et al. (medRxiv, 2023)
The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or “autoreactome”, that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody repertoires. We find that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual’s autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases.Competing Interest StatementJ.D.R. reports being a founder and paid consultant for Delve Bio, Inc., and a paid consultant for the Public Health Company and Allen & Co. M.A.S. receives unrelated research funding from the NIH, the CDC, Cepheid and Merck and unrelated Honoria from UpToDate, Inc. M.R.W. reports being a founder and paid consultant for Delve Bio, Inc. and receives unrelated research grant funding from Roche/Genentech and Novartis, and received speaking honoraria from Genentech, Takeda, WebMD, and Novartis. C.J.T. reports being on the Scientific Advisory Boards for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics, Celgene/BMS Cell Therapy; is a member a DSMB member of Kyverna; is on Ad hoc advisory boards/consulting (last 12 months) for Nektar Therapeutics, Legend Biotech, Prescient Therapeutics, Century Therapeutics, IGM Biosciences, Abbvie; has Stock options in Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics; and reports the right to receive payment from Fred Hutch as an inventor on patents related to CAR T-cell therapy. J.A.H. reports research funding from Merck and Takeda and consulting fees from Takeda, Gilead, SentiBio, and Century Therapeutics. J.G. reports research funding from Sobi, Juno Therapeutics (a BMS company), Celgene (a BMS company), Angiocrine Bioscience; is an Ad hoc consultant for Sobi, Legend Biotech, Janssen, Kite Pharma, MorphoSys. D.J.G. has received research funding, has served as an advisor and has received royalties from Juno Therapeutics, a Bristol-Myers Squibb company; has served as an advisor and received research funding from Seattle Genetics; has served as an advisor for GlaxoSmithKline, Celgene, Janssen Biotech, Ensoma and Legend Biotech; and has received research funding from SpringWorks Therapeutics, Sanofi, and Cellectar Biosciences. K.C.O. received unrelated research funding from, and is an equity shareholder of Cabaletta Bio, and receives unrelated research funding from Seismic, argenx, and Viela Bio/Horizon (now Amgen). R.J.N. reports unrelated research support from the National Institutes of Health, Genentech, Inc., Alexion Pharmaceuticals, Inc., argenx, Annexon Biosciences, Inc., Ra Pharmaceuticals, Inc. (now UCB S.A.), the Myasthenia Gravis Foundation of America, Inc., Momenta Pharmaceuticals, Inc. (now Janssen), Immunovant, Inc., Grifols, S.A., and Viela Bio, Inc. (now Horizon Therapeutics plc). R.J.N. has also served as a consultant/advisor unrelated to research in this manuscript for Alexion Pharmaceuticals, Inc., argenx, Cabaletta Bio, Inc., Cour Pharmaceuticals, CSL Behring, Grifols, S.A., Ra Pharmaceuticals, Inc. (now UCB S.A.), Immunovant, Inc., Momenta Pharmaceuticals, Inc. (now Janssen), and Viela Bio, Inc. (now Horizon Therapeutics plc). J.L.D., C.M.B. and M.R.W. receive licensing fees from CDI Labs.Funding StatementThis work was supported by the Pediatric Scientist Development Program and the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant K12-HD000850 (A.B.), and by the Chan Zuckerberg Biohub SF (J.L.D. and M.S.A.), and by National Institutes of Health grants R01AR073938 and R01AR075813 (S.W.J) and by and the National Cancer Institute (U01CA247548 to J.A.H.) and by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers R01-AI114780(K.C.O), R21-AI142198(K.C.O), R21 AI164590 (K.C.O) and through an awards provided through award number U54-NS115054 (K.C.O) and NIH U54 NS115054 (G.M and R.J.N; G.M is also an MGNet Scholar Awardee) of the Rare Diseases Clinical Research Network Consortium (RDCRN) of the NIH and MGNet. All RDCRN consortia are supported by the networks Data Management and Coordinating Center (DMCC) (U2CTR002818). This study was supported by NIH-NIA grants R01AG032289 (J.H.K) and R01AG072475(K.B.C), UCSF ADRC P30AG062422 (G.D.R). This work was also supported by a grant from the Larry L. Hillblom Foundation (2018-A-006-NET; J.H.K). This work was also supported by the Henry Gustav Floren Trust, the Stanford Department of Medicine Team Science Program, and funding from the Stanford Medicine Office of the Dean (P.J.U.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB (IRB #10-02076) of University of California in San Francisco gave ethical approval for this work. Ethics committee/IRB (Protocol 10080) of the Fred Hutchinson Cancer Center gave ethical approval for this work. Ethics committee/IRB (EXPLORE-MG Registry, NCT03792659) of Yale University gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll PhIP-Seq data will be made publicly available upon publication of this manuscript via a Dryad digital repository; DOI: 10.5061/dryad.w3r2280z6 https://dx.doi.org/10.5061/dryad.w3r2280z6